Neal Moszkowski has retired from the Board of Directors of Integra LifeSciences Holding Corporation and has been replaced as a Director of the Company by Donald Morel. “Neal’s service to Integra for a total of 13 years has been extremely valuable, ” said Stuart Essig, Chairman of Integra’s Board of Directors. “We are thankful for his contributions to the Company during his tenure on the Board and its Nominating and Corporate Governance and Compensation Committees.”
Integra Board Swap: Moszkowski Leaves, Morel Joins
1 min read Premium comments
Secondary
Peter Arduini, Integra’s President and CEO said of Morel, “He is a healthcare executive with extensive management and product development experience. He has a particular interest and expertise in biomaterials. His tenure at West Pharmaceutical and broad experience in our industry will add a valuable perspective on Integra. I am delighted that he has agreed to join our Board of Directors.”
Morel is currently the CEO and Chairman of the Board of Directors of West Pharmaceutical Services, Inc., a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries.
He also served as a Director of Kensey Nash Corporation, a medical device product development and manufacturing company and was a member of its audit and compensation committees. He is Chairman of the Board of Directors of the American Oncologic Hospital of the Fox Chase Cancer Center and is a member of the board of trustees of The Franklin Institute and of Lafayette College. Morel received a B.S. in Engineering from Lafayette College and an M.S. and Ph.D. in Materials Science from Cornell University.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.